Q: What is Sublocade used for?

Sublocade is used to treat opioid use disorder .

Q: How does Sublocade work?

Mechanism of Action Sublocade is a long-acting injection of buprenorphine, a medication classified as a partial opioid agonist. It works by binding to the same receptors in the brain that are affected by other opioids, such as heroin or prescription pain relievers. By occupying these receptors, buprenorphine helps to: Reduce cravings: It satisfies the brain's need for opioids without producing the same intense high as full opioids. Prevent withdrawal: It provides enough stimulation to the receptors to stop the physical symptoms of withdrawal. Block other opioids: Because it binds strongly to the receptors, it can block the effects of other opioids if they are taken while Sublocade is in the system. Extended-Release Delivery The medication uses a delivery system that turns into a solid mass, known as a depot, once it is injected under the skin. This depot slowly dissolves over time, releasing a consistent amount of buprenorphine into the bloodstream throughout the month. This steady level helps maintain stability and avoids the daily highs and lows sometimes associated with oral medications. The Ceiling Effect As a partial agonist, buprenorphine has a ceiling effect. This means that after a certain dose, its effects do not increase further. This characteristic makes it less likely to cause dangerous slowed breathing ( respiratory depression ) compared to full opioid agonists.

Q: What are the active ingredients in Sublocade?

The active ingredient in Sublocade is buprenorphine .

Q: What are the side effects of Sublocade?

Common side effects of Sublocade may include: Constipation Headache Nausea Others Always consult with a healthcare professional about potential side effects.

Q: What drug class is Sublocade?

Sublocade belongs to the opioid partial agonist drug class.

Q: What is the dosage of Sublocade and how do I take it?

Administration Sublocade is given as a subcutaneous injection, meaning it is injected into the fatty tissue just under the skin of the abdomen. This medication must be administered by a healthcare professional in a medical setting. It is not designed for self-administration, and attempting to inject it yourself can cause serious health risks. Dosing Schedule The injection is typically administered once every month. Your healthcare provider will manage your schedule to ensure there is a sufficient amount of time between each dose. Starting Treatment Before receiving your first injection, you must be stabilized on a transmucosal buprenorphine medication (such as a tablet or film that dissolves under the tongue or in the cheek) for a period of time. This stabilization period helps ensure the medication is safe and effective for you before transitioning to the long-acting monthly injection. Injection Site Care After the injection, the medication forms a small, solid lump under the skin called a depot. This lump slowly releases the medicine into your body over several weeks. It is important not to rub, massage, or apply pressure to the injection site. You should also avoid wearing tight clothing or belts that might irritate the area where the medication was injected. Missed Doses If you miss an appointment for your injection, contact your healthcare provider immediately to reschedule. While the medication stays in your system for a long time, maintaining a consistent schedule is important for the success of your treatment program.

Q: Is Sublocade safe during pregnancy and breastfeeding?

Pregnancy Considerations If Sublocade is used during pregnancy, the baby may experience neonatal opioid withdrawal syndrome (NOWS) after birth. This is a recognized and treatable condition that can occur with the use of opioid medications during pregnancy. Healthcare providers monitor newborns for signs of withdrawal, which may include: High-pitched crying and irritability Abnormal sleep patterns Tremors or jitteriness Vomiting or diarrhea Failure to gain weight It is important not to stop treatment for opioid use disorder during pregnancy without medical guidance. Untreated addiction can lead to serious complications for both the pregnant person and the fetus. Decisions regarding the use of Sublocade should be made in consultation with a medical professional to balance the benefits of treatment against the risks of withdrawal for the newborn. Breastfeeding Buprenorphine, the active ingredient in Sublocade, passes into breast milk in small amounts. While breastfeeding is often possible for those on stable treatment, it is important to monitor the nursing infant closely. Parents should watch for signs of: Increased sleepiness or difficulty waking up Difficulty breathing or slow breathing Limpness or poor feeding Discuss the risks and benefits of breastfeeding with a healthcare provider to determine the safest approach for the infant and the parent.

Q: What forms and strengths does Sublocade come in?

Available Forms Sublocade is available in the following form: Extended-release subcutaneous injection: This medication is provided as a liquid in a prefilled, single-use syringe. The injection is administered by a healthcare provider under the skin of the abdomen. After injection, the delivery system forms a solid mass known as a depot, which slowly releases the medication into the body over a period of time. Due to safety requirements, this medication is not available for self-administration and must be administered in a clinical setting by a trained professional.

Q: What is the FDA approval status of Sublocade?

FDA Approval and Indication The U.S. Food and Drug Administration (FDA) approved Sublocade in November 2017. It is indicated for the treatment of moderate to severe opioid use disorder (OUD) in adult patients who have initiated treatment with a transmucosal buprenorphine-containing product and have been on a stable dose for at least seven days. Boxed Warning and Administration Sublocade carries a Boxed Warning regarding the risk of serious harm or death if the medication is administered intravenously. Because the medication forms a solid mass upon contact with body fluids, an intravenous injection could cause a blood clot, damage to local tissues, or a pulmonary embolism. To mitigate this risk, Sublocade must only be administered by a healthcare provider as a subcutaneous injection in the abdominal region. REMS Program Due to the risks associated with improper administration, Sublocade is only available through a restricted distribution program called the Sublocade Risk Evaluation and Mitigation Strategy (REMS) Program. Healthcare settings and pharmacies that dispense the medication must be certified in the program to ensure it is only administered by healthcare providers and not dispensed directly to patients. Regulatory Safety Communications The FDA has issued communications regarding medications for opioid use disorder (MOUD), emphasizing that these treatments should generally not be withheld from patients taking benzodiazepines or other central nervous system depressants. While combining these substances increases the risk of serious side effects, the FDA advises that the benefits of OUD treatment often outweigh these risks, provided that healthcare providers manage the treatment plan carefully.

Question 1

What is Sublocade?

Accepted Answer

Sublocade is a medication containing buprenorphine, which belongs to a class of drugs known as partial opioid agonists. It works by interacting with the same receptors in the brain as other opioids to help manage physical symptoms and cravings.

This medication is used as part of a comprehensive treatment plan that includes counseling and psychosocial support. It is designed to provide a continuous release of medicine over time to support long-term recovery goals.

Question 2

What is Sublocade used for?

Accepted Answer

Sublocade is used to treat opioid use disorder.

Question 3

How does Sublocade work?

Accepted Answer

Mechanism of Action

Sublocade is a long-acting injection of buprenorphine, a medication classified as a partial opioid agonist. It works by binding to the same receptors in the brain that are affected by other opioids, such as heroin or prescription pain relievers.

By occupying these receptors, buprenorphine helps to:

Reduce cravings: It satisfies the brain's need for opioids without producing the same intense high as full opioids.
Prevent withdrawal: It provides enough stimulation to the receptors to stop the physical symptoms of withdrawal.
Block other opioids: Because it binds strongly to the receptors, it can block the effects of other opioids if they are taken while Sublocade is in the system.

Extended-Release Delivery

The medication uses a delivery system that turns into a solid mass, known as a depot, once it is injected under the skin. This depot slowly dissolves over time, releasing a consistent amount of buprenorphine into the bloodstream throughout the month. This steady level helps maintain stability and avoids the daily highs and lows sometimes associated with oral medications.

The Ceiling Effect

As a partial agonist, buprenorphine has a ceiling effect. This means that after a certain dose, its effects do not increase further. This characteristic makes it less likely to cause dangerous slowed breathing (respiratory depression) compared to full opioid agonists.

Question 4

What are the active ingredients in Sublocade?

Accepted Answer

The active ingredient in Sublocade is buprenorphine.

Question 5

What are the side effects of Sublocade?

Accepted Answer

Common side effects of Sublocade may include:

Constipation
Headache
Nausea
Others

Always consult with a healthcare professional about potential side effects.

Question 6

What drug class is Sublocade?

Accepted Answer

Sublocade belongs to the opioid partial agonist drug class.

Question 7

What is the dosage of Sublocade and how do I take it?

Accepted Answer

Administration

Sublocade is given as a subcutaneous injection, meaning it is injected into the fatty tissue just under the skin of the abdomen. This medication must be administered by a healthcare professional in a medical setting. It is not designed for self-administration, and attempting to inject it yourself can cause serious health risks.

Dosing Schedule

The injection is typically administered once every month. Your healthcare provider will manage your schedule to ensure there is a sufficient amount of time between each dose.

Starting Treatment

Before receiving your first injection, you must be stabilized on a transmucosal buprenorphine medication (such as a tablet or film that dissolves under the tongue or in the cheek) for a period of time. This stabilization period helps ensure the medication is safe and effective for you before transitioning to the long-acting monthly injection.

Injection Site Care

After the injection, the medication forms a small, solid lump under the skin called a depot. This lump slowly releases the medicine into your body over several weeks. It is important not to rub, massage, or apply pressure to the injection site. You should also avoid wearing tight clothing or belts that might irritate the area where the medication was injected.

Missed Doses

If you miss an appointment for your injection, contact your healthcare provider immediately to reschedule. While the medication stays in your system for a long time, maintaining a consistent schedule is important for the success of your treatment program.

Question 8

Is Sublocade safe during pregnancy and breastfeeding?

Accepted Answer

Pregnancy Considerations

If Sublocade is used during pregnancy, the baby may experience neonatal opioid withdrawal syndrome (NOWS) after birth. This is a recognized and treatable condition that can occur with the use of opioid medications during pregnancy. Healthcare providers monitor newborns for signs of withdrawal, which may include:

High-pitched crying and irritability
Abnormal sleep patterns
Tremors or jitteriness
Vomiting or diarrhea
Failure to gain weight

It is important not to stop treatment for opioid use disorder during pregnancy without medical guidance. Untreated addiction can lead to serious complications for both the pregnant person and the fetus. Decisions regarding the use of Sublocade should be made in consultation with a medical professional to balance the benefits of treatment against the risks of withdrawal for the newborn.

Breastfeeding

Buprenorphine, the active ingredient in Sublocade, passes into breast milk in small amounts. While breastfeeding is often possible for those on stable treatment, it is important to monitor the nursing infant closely. Parents should watch for signs of:

Increased sleepiness or difficulty waking up
Difficulty breathing or slow breathing
Limpness or poor feeding

Discuss the risks and benefits of breastfeeding with a healthcare provider to determine the safest approach for the infant and the parent.

Question 9

What forms and strengths does Sublocade come in?

Accepted Answer

Available Forms

Sublocade is available in the following form:

Extended-release subcutaneous injection: This medication is provided as a liquid in a prefilled, single-use syringe.

The injection is administered by a healthcare provider under the skin of the abdomen. After injection, the delivery system forms a solid mass known as a depot, which slowly releases the medication into the body over a period of time.

Due to safety requirements, this medication is not available for self-administration and must be administered in a clinical setting by a trained professional.

Question 10

What is the FDA approval status of Sublocade?

Accepted Answer

FDA Approval and Indication

The U.S. Food and Drug Administration (FDA) approved Sublocade in November 2017. It is indicated for the treatment of moderate to severe opioid use disorder (OUD) in adult patients who have initiated treatment with a transmucosal buprenorphine-containing product and have been on a stable dose for at least seven days.

Boxed Warning and Administration

Sublocade carries a Boxed Warning regarding the risk of serious harm or death if the medication is administered intravenously. Because the medication forms a solid mass upon contact with body fluids, an intravenous injection could cause a blood clot, damage to local tissues, or a pulmonary embolism. To mitigate this risk, Sublocade must only be administered by a healthcare provider as a subcutaneous injection in the abdominal region.

REMS Program

Due to the risks associated with improper administration, Sublocade is only available through a restricted distribution program called the Sublocade Risk Evaluation and Mitigation Strategy (REMS) Program. Healthcare settings and pharmacies that dispense the medication must be certified in the program to ensure it is only administered by healthcare providers and not dispensed directly to patients.

Regulatory Safety Communications

The FDA has issued communications regarding medications for opioid use disorder (MOUD), emphasizing that these treatments should generally not be withheld from patients taking benzodiazepines or other central nervous system depressants. While combining these substances increases the risk of serious side effects, the FDA advises that the benefits of OUD treatment often outweigh these risks, provided that healthcare providers manage the treatment plan carefully.

Question 11

What should I know about Sublocade and withdrawal?

Accepted Answer

Withdrawal Symptoms

Stopping Sublocade can cause opioid withdrawal symptoms as the medication levels in your body decrease. These symptoms may include:

Nausea, vomiting, or diarrhea
Muscle aches and joint pain
Sweating, chills, or goosebumps
Anxiety, irritability, or restlessness
Sleep disturbances
Runny nose or watery eyes

Delayed Onset

Because Sublocade is an extended-release injection, the medication stays in your system for a long time. Withdrawal symptoms may not appear immediately after a missed dose; instead, they might emerge weeks or even months after your last injection. Your healthcare provider will typically monitor you for several months after your final dose to manage any late-emerging withdrawal signs or cravings.

Safety Considerations

You should not stop treatment abruptly or without medical guidance. If treatment is discontinued, your doctor will monitor you for signs of withdrawal and the potential return of opioid use disorder. It is important to keep all follow-up appointments even after you stop receiving the injections.

Sublocade

📋Overview

How It Works

Uses

Active Ingredients

Common Side Effects

Warnings & Precautions

Dosage

Pregnancy & Breastfeeding

Frequently Asked Questions

📚References

Found an Error?

Find Discounts for Sublocade

Hospitals.net Disclosure